Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
propiverine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Propiverine/tolterodine group | ACTIVE_COMPARATOR | - |
| Tolerodine/propiverine group | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| propiverine | DRUG | Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week. |
| tolterodine PR | DRUG | Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week. |
Inclusion Criteria: * Symptoms of urinary urgency * Symptoms of urinary frequency (greater than or equal to 8 micturitions per 24 hours) as verified on the patient's micturition chart * Symptoms of overactive bladder for greater than or equal to 6 months Exclusion Criteria: * Stress incontinence ...
Propiverine is an investigational small molecule being studied for the treatment of overactive bladder. It is in Phase 3 clinical development and has been evaluated in a completed clinical trial for this condition.
Propiverine is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical development for overactive bladder.
Propiverine is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 clinical trial for propiverine has been completed.
Propiverine has been studied in a completed Phase 3 clinical trial registered as NCT00646880. This trial evaluated the efficacy of propiverine compared with tolterodine prolonged release in Korean patients with overactive bladder, using ambulatory urodynamic monitoring.
Propiverine is not the same as tolterodine. In a completed Phase 3 clinical trial, propiverine was compared with tolterodine prolonged release as an active control for the treatment of overactive bladder in Korean patients.